Smart investing isn’t just knowing what stocks to buy. It’s also knowing what stocks to avoid…

That’s why we’ve put together a list of stocks on death watch in 2016. While companies on this list aren’t guaranteed to fail, they have a high likelihood of doing so.

We’ll come out with a new stock death watch list every month, so be sure to check back often.

Here are three stocks on death watch in October 2016…

Death Watch Stocks, October 2016

Stocks on Death Watch No. 1: Valeant Pharmaceuticals International Inc. (NYSE: VRX)

Valeant is a drug company that makes both branded and generic drugs. It also makes certain medical devices, like contact lenses and surgical equipment. The company is known for its focus on distribution, rather than research and development, which former CEO Michael Pearson said makes it more efficient and profitable.

Top Medical Stocks To Buy Right Now: iShares 20+ Year Treasury Bond (TLT)

Advisors’ Opinion:

• [By WWW.GURUFOCUS.COM]

  For the details of Nationwide Fund Advisors’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Nationwide+Fund+Advisors

  These are the top 5 holdings of Nationwide Fund AdvisorsiShares Core MSCI Emerging Markets (IEMG) – 4,698,924 shares, 74.25% of the total portfolio. Shares added by 119.53%iShares 20+ Year Treasury Bond ETF (TLT) – 536,574 shares, 17.7% of the total portfolio. Shares added by 79.94%iShares iBoxx $ High Yield Corporate Bond (HYG) – 347,518 shares, 8.05% of the total portfolio. Shares reduced by 20.57%

• [By Dan Caplinger]

  In general, the longer a bond has until maturity, the more sensitive it is to interest rate movements. That has generally held true for Treasuries in 2018. The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT), which holds Treasury bonds with the longest maturities available, has seen its price fall 8% so far this year. Even when you take into account the income that bond ETFs provide, the iShares fund’s total return is still -7%.

• [By Stephan Byrd]

  NEXT Financial Group Inc raised its position in Ishares Lehman 20 Year (NASDAQ:TLT) by 30.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 10,785 shares of the exchange traded fund’s stock after acquiring an additional 2,489 shares during the period. NEXT Financial Group Inc’s holdings in Ishares Lehman 20 Year were worth $1,315,000 at the end of the most recent reporting period.

• [By Shane Hupp]

  iShares Barclays 20+ Yr Treas.Bond (NASDAQ:TLT) announced a monthly dividend on Monday, July 2nd, Wall Street Journal reports. Stockholders of record on Tuesday, July 3rd will be given a dividend of 0.2749 per share by the exchange traded fund on Monday, July 9th. This represents a $3.30 annualized dividend and a dividend yield of 2.72%. The ex-dividend date of this dividend is Monday, July 2nd.

• [By Luke Kawa]

  All of these low-duration ETFs are trouncing their peers that carry a high degree of interest rate risk — like Vanguard’s Long-Term Bond ETF (BLV) and the iShares 20+ Year Treasury Bond ETF (TLT) — out of the gate in 2018.

Top Medical Stocks To Buy Right Now: Galmed Pharmaceuticals Ltd.(GLMD)

Advisors’ Opinion:

• [By Shane Hupp]

  Here are some of the media stories that may have effected Accern’s rankings:

  Get Galmed Pharmaceuticals alerts:

  Galmed Pharmaceuticals’ (GLMD) CEO Allen Baharaff on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) What You Must Know About Galmed Pharmaceuticals Ltds (NASDAQ:GLMD) Market Risks (finance.yahoo.com) Obeticholic Acid Market Analysis, Recent Trends and Regional Growth Forecast by Types, Applications and Economic … (theexpertconsulting.com) oholic Steatohepatitis (NASH) Market 2023: Know Marketing Channel Future Trend, Growth and Price with Future … (theexpertconsulting.com) Umbilical Cord Blood May Offer Early FH Diagnosis (medscape.com)

  A number of equities analysts have recently commented on GLMD shares. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, HC Wainwright lifted their price target on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.40.

• [By Sean Williams]

  Similar strength was seen from microcap Galmed Pharmaceuticals (NASDAQ:GLMD), which rose by more than 150% during a single trading session two weeks ago despite mixed results. The move followed the release of phase 2b data from its 52-week Arrest study for NASH drug hopeful Aramchol. In that trial, a statistically significant reduction in liver fat was noted with one of the two doses (the 400 mg dose). However, the 600 mg dose led to a statistically significant improvement in overall NASH resolution (19.2% vs. 7.5%) and NASH resolution without worsening of fibrosis (16.7% vs. 5%) relative to the placebo.

• [By Keith Speights]

  That’s exactly what happened this week with three small biotech stocks. Galmed Pharmaceuticals (NASDAQ:GLMD), Galectin Therapeutics (NASDAQ:GALT), and Eloxx Pharmaceuticals (NASDAQ:ELOX) soared on news that excited investors. Here’s what drove these stocks higher — and whether or not they’re smart picks for investors now.

• [By George Budwell]

  Over the last two weeks, shares ofMadrigal Pharmaceuticals (NASDAQ:MDGL), Galmed Pharmaceuticals (NASDAQ:GLMD), and Viking Therapeutics (NASDAQ:VKTX) have more than doubled in value. The reason?

• [By Jon C. Ogg]

  Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) was started as Outperform with a $26 price target at Raymond James on July 20, and that was versus a previous $15.02 closing price. A week earlier, onJune 13, Stifel Nicolaus initiated Galmed with a Buy rating and issued a $35 price target that would imply more than 100% upside. Galmed has been quite volatile as its 52-week range is listed at $3.61 to $27.06. It had a $322 million market cap as ofFriday. Galmed, which focuses on diseases and issues targeting the liver, closed at $15.00on Friday. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria.

• [By George Budwell]

  Shares of the clinical-stage biotech Galmed Pharmaceuticals (NASDAQ:GLMD) are on absolute fire this morning, thanks to a positive midstage trial readout for its experimental nonalcoholic steatohepatitis (NASH) drug Aramchol. Specifically, the company reported that patients receiving the 400 mg dose of Aramchol exhibited a significant reduction in liver fat over the study period compared to those taking a placebo. Curiously, though, patients receiving the higher dose of 600 mg apparently only showed a statistically significant drop in liver fat relative to placebo patients in a post-hoc analysis, according to the press release.

Top Medical Stocks To Buy Right Now: Dril-Quip, Inc.(DRQ)

Advisors’ Opinion:

• [By Logan Wallace]

  Gabelli Funds LLC grew its holdings in Dril-Quip, Inc. (NYSE:DRQ) by 4.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 55,500 shares of the oil and gas company’s stock after purchasing an additional 2,500 shares during the period. Gabelli Funds LLC owned about 0.15% of Dril-Quip worth $2,486,000 at the end of the most recent quarter.

• [By Shane Hupp]

  Solaris Oilfield Infrastructure (NYSE: SOI) and Dril-Quip (NYSE:DRQ) are both small-cap oils/energy companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Dril-Quip (DRQ)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Shane Hupp]

  Dril-Quip, Inc. (NYSE:DRQ) – Stock analysts at Piper Jaffray issued their Q2 2018 earnings per share (EPS) estimates for Dril-Quip in a research note issued on Monday, May 14th. Piper Jaffray analyst I. Macpherson anticipates that the oil and gas company will post earnings per share of ($0.11) for the quarter. Piper Jaffray currently has a “Hold” rating and a $40.00 price target on the stock. Piper Jaffray also issued estimates for Dril-Quip’s Q3 2018 earnings at ($0.08) EPS, Q4 2018 earnings at ($0.09) EPS, Q1 2019 earnings at ($0.03) EPS, Q2 2019 earnings at $0.02 EPS, Q3 2019 earnings at $0.08 EPS, Q4 2019 earnings at $0.08 EPS and FY2020 earnings at $0.64 EPS.

Top Medical Stocks To Buy Right Now: Oasis Petroleum Inc.(OAS)

Advisors’ Opinion:

• [By Stephan Byrd]

  These are some of the media stories that may have impacted Accern Sentiment’s scoring:

  Get Oasis Petroleum alerts:

  Oasis Petroleum CEO: Oil prices always come back to suppl… (finance.yahoo.com) Oasis Petroleum (OAS) Price Target Raised to $17.00 at JPMorgan Chase (americanbankingnews.com) Oasis Petroleum (OAS) Rating Increased to Overweight at Morgan Stanley (americanbankingnews.com) Oasis Petroleum (OAS) Given Buy Rating at Williams Capital (americanbankingnews.com) Oasis Petroleum (OAS) Forecasted to Post FY2018 Earnings of $0.44 Per Share (americanbankingnews.com)

  Several equities research analysts have recently commented on the stock. Stephens set a $15.00 price target on shares of Oasis Petroleum and gave the stock a “buy” rating in a research report on Tuesday, April 24th. Williams Capital reiterated a “buy” rating and set a $18.00 price target on shares of Oasis Petroleum in a research report on Wednesday. JPMorgan Chase & Co. set a $17.00 price target on shares of Oasis Petroleum and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley upgraded shares of Oasis Petroleum from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $12.52 to $19.00 in a research report on Wednesday. Finally, BMO Capital Markets lifted their price target on shares of Oasis Petroleum from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 1st. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and sixteen have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $12.41.

• [By Garrett Baldwin]

  Oil prices are at levels we haven’t seen in years. U.S. crude topped $70 for the first since 2014, as U.S. President Donald Trump appeared increasingly likely to pull out of the Iran nuclear deal and reinforce sanctions on Tehran. In addition, OPEC has announced plans to bolster prices and cap production. For oil investors, Money MorningGlobal Energy Strategist Dr. Kent Moors says it’s time to buckle up. According to Moors, revoking the Iran deal would cause “price chaos” around the globe. And that’s right as driving season starts in the United States. Here’s more on the coming chaos for oil. In deal news, Blackstone Group (NYSE: BX) announced it will purchase Gramercy Property Trust (NYSE: GPT) for $7.6 billion in cash. Grammercy manages commercial real estate. While this may seem like a boring deal, Blackstone is buying a business that churns out cold hard cash for its investors. We want to keep this deal on your radar, because there are many other deals like this coming down the pipeline. We’re going to be discussing one of the best real estate opportunities available very soon – so keep an eye out for updates.
  Three Stocks to Watch Today: AMZN, AAPL, TSN, SBUX
  Shareholders of Amazon.com Inc. (Nasdaq: AMZN) cheered statements made by Warren Buffett over the weekend. The Oracle of Omaha said he messed up by not investing in Amazon and Alphabet Inc. (Nasdaq: GOOGL). “I made the wrong decisions on Google and Amazon,” Buffett said on Saturday. “We’ve looked at it. I made the mistake in not being able to come to a conclusion where I really felt that at the present prices that the prospects were far better than the prices indicated.” Buffett says he now has a “very, very, very high opinion” of Amazon CEO Jeff Bezos. The Oracle believes that Bezos has created something that is “close to a miracle.” Apple Inc. (Nasdaq: AAPL) added another 0.6% Monday, to reach $185.00 per share – a new 52-week high. The uptick came after Warren Buffett announced

• [By Benzinga News Desk]

  The curtain could come down any day on MoviePass’ bumpy run as an independent company: Link

  ECONOMIC DATA
  Chicago Fed national activity index +0.10 vs +0.27 expected
  The Composite Purchasing Managers' Index for April will be released at 9:45 a.m. ET.
  Existing home sales report for March is schedule for release at 10:00 a.m. ET.
  The Treasury is set to auction 3-and 6-month bills at 11:30 a.m. ET.
  ANALYST RATINGS
  Deutsche Bank upgraded Michael Kors (NYSE: KORS) from Hold to Buy
  RBC downgraded Paylocity (NASDAQ: PCTY) from Outperform to Sector Perform
  Suntrust downgraded Oasis Petroleum (NYSE: OAS) from Hold to Sell

  This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

• [By Ethan Ryder]

  Shares of Oasis Petroleum (NYSE:OAS) hit a new 52-week high and low during trading on Thursday . The company traded as low as $13.39 and last traded at $13.08, with a volume of 278190 shares traded. The stock had previously closed at $12.90.

• [By Lee Jackson]

  Oasis Petroleum Inc. (NYSE: OAS) was downgraded to Hold from Buy at Jefferies, with a $14 price target. The Wall Street consensus target is set at $14.56. The shares closed trading on Friday at $12.86.

• [By Jon C. Ogg]

  Oasis Petroleum Corp. (NYSE: OAS) was raised to Overweight from Equal Weight with a $19 target price (versus a $12.52 close) at Morgan Stanley.

  Old Dominion Freight Line Inc. (NASDAQ: ODFL) was started as Buy at Argus.

Top Medical Stocks To Buy Right Now: Forward Pharma A/S(FWP)

Advisors’ Opinion:

• [By Lisa Levin]

  Check out these big penny stock gainers and losers

  Losers
  Forward Pharma A/S (NASDAQ: FWP) fell 15.2 percent to $3.51 in pre-market trading after surging 88.18 percent on Tuesday.
  Pfenex Inc. (NASDAQ: PFNX) shares fell 15 percent to $5.85 in pre-market trading after the company announced an offering of common stock.
  Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) fell 17.6 percent to $47.75 in pre-market trading after the company reported downbeat results for its first quarter and issued a weak earnings forecast for the second quarter.
  Container Store Group, Inc. (NYSE: TCS) fell 13 percent to $7.15 in pre-market trading after reporting weaker-than-expected earnings for its fourth quarter.
  Ardelyx, Inc. (NASDAQ: ARDX) shares fell 12.1 percent to $4.00 in pre-market trading after reporting pricing of public offering of common stock.
  Boston Scientific Corporation (NYSE: BSX) shares fell 9.8 percent to $27.31 in pre-market trading.
  Turkcell Iletisim Hizmetleri A.S. (NYSE: TKC) fell 6.5 percent to $6.60 in pre-market trading.
  Target Corporation (NYSE: TGT) shares fell 5.8 percent to $71.02 in pre-market trading. Target reported weaker-than-expected earnings for its first quarter, while sales exceeded estimates.
  PBF Energy Inc. (NYSE: PBF) shares fell 5.7 percent to $42.42 in pre-market trading

• [By Lisa Levin] Gainers
  Forward Pharma A/S (NASDAQ: FWP) shares gained 88.18 percent to close at $4.14 on Tuesday.
  Regional Health Properties, Inc. (NYSE: RHE) shares jumped 18.04 percent to close at $0.3010 on Tuesday.
  Precipio, Inc. (NASDAQ: PRPO) shares gained 16.61 percent to close at $0.49 after the nano-cap specialty diagnostics company said it saw an acceleration of sales in its Pathology services in April. The company now expects to see a sequential double digit quarterly sales growth.
  Arcturus Therapeutics Ltd. (NASDAQ: ARCT) rose 16.09 percent to close at $7.00 on Tuesday.
  America's Car-Mart, Inc. (NASDAQ: CRMT) gained 14.53 percent to close at $62.65 after reporting upbeat Q4 results.
  NanoString Technologies, Inc. (NASDAQ: NSTG) shares surged 12.64 percent to close at $13.19.
  Geron Corporation (NASDAQ: GERN) gained 12.12 percent to close at $4.07 on Tuesday.
  Quotient Limited (NASDAQ: QTNT) shares climbed 11.58 percent to close at $6.55 on Tuesday.
  American Equity Investment Life Holding Company (NYSE: AEL) rose 11.23 percent to close at $32.28 following a report from Reuters that the company is looking for a sale.
  iQIYI, Inc. (NASDAQ: IQ) gained 11.15 percent to close at $22.52.
  Veracyte, Inc. (NASDAQ: VCYT) rose 10.4 percent to close at $7.11.
  Stein Mart, Inc. (NASDAQ: SMRT) gained 10.26 percent to close at $3.33. Stein Mart is expected to release quarterly earnings on May 23.
  MiMedx Group, Inc. (NASDAQ: MDXG) shares rose 10.11 percent to close at $8.06.
  The Container Store Group, Inc. (NYSE: TCS) gained 8.2 percent to close at $8.18. Container Store reported weaker-than-expected earnings for its fourth quarter after the closing bell.
  Photronics, Inc. (NASDAQ: PLAB) shares gained 7.69 percent to close at $9.10 after the company reported upbeat Q2 results.
  Micron Technology, Inc. (NASDAQ: MU) rose 6.4 percent to close at $59.03 after reporting a $10 billion buyback plan.

   

Top Medical Stocks To Buy Right Now: Regions Financial Corporation(RF)

Advisors’ Opinion:

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Regions Financial (RF)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  ValuEngine upgraded shares of Regions Financial (NYSE:RF) from a hold rating to a buy rating in a report released on Wednesday.

  A number of other analysts also recently commented on RF. Keefe, Bruyette & Woods reiterated a neutral rating on shares of Regions Financial in a report on Sunday, April 22nd. B. Riley increased their price objective on shares of Regions Financial from $19.00 to $20.00 and gave the company a neutral rating in a report on Tuesday, April 24th. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. Regions Financial has a consensus rating of Hold and an average price target of $17.56.

• [By Shane Hupp]

  Regions Financial (NYSE:RF) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, July 20th. Analysts expect the company to announce earnings of $0.33 per share for the quarter.

• [By ]

  Regions Financial (RF) : “I think this one is real good. I like the banks here.”

  Edwards Lifesciences (EW) : “They have the best devices. That stock is a buy.”

• [By ]

  Regions Financial (NYSE: RF) could be a beneficiary of the move to deregulation in banking this year and is expected to grow earnings by 24% to $1.35 per share. The bank is seeing strong growth in non-interest income sources and management has a plan to cut up to 10% in operating expenses for greater profitability. Regions has a strong deposit base across the Southeast and averages a 7% return on equity, well above the industry average.